Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human papillomavirus 9-valent vaccine, recombinant
- Development stage
- Approved
- Lead developer
- Recbio
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
REC603 is a recombinant 9-valent human papillomavirus (HPV) vaccine developed by Jiangsu Recbio Technology. It is designed to protect against nine HPV types: 6, 11, 16, 18, 31, 33, 45, 52, and 58. Unlike the first-generation 9-valent vaccine (Gardasil 9), which is produced in Saccharomyces cerevisiae, REC603 is expressed using a Hansenula polymorpha (Hansenula yeast) platform, which is intended to offer higher yields and improved scalability. The vaccine consists of virus-like particles (VLPs) formed by the L1 capsid proteins of the targeted HPV types. It is currently in Phase III clinical trials in China for the prevention of HPV-related diseases, including cervical, vulvar, vaginal, and anal intraepithelial neoplasia, as well as anogenital warts.
- Other names
- recombinant human papillomavirus 9-valent (types 6,11,16,18,31,33,45,52,58) vaccine (Hansenula)
02
Targets
HPV11 L1HPV16 (Human papillomavirus type 16)HPV18 L1HPV31 L1HPV33 L1HPV45 L1HPV52 L1 (Human papillomavirus type 52 major capsid protein L1)HPV58 L1 (Human papillomavirus type 58 major capsid protein L1)HPV6 L1 (Human papillomavirus type 6 major capsid protein L1)
Beyond the preview
Go deeper on human papillomavirus 9-valent vaccine, recombinant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human papillomavirus 9-valent vaccine, recombinant.